Genmab (GMAB) return on equity (ROE)

Return on equity · fiscal 2025
16.5%

Genmab (GMAB) earned a return on equity of 16.5% in fiscal 2025 (the year ended December 31, 2025). That is 5.6 percentage points lower than the 22.1% of fiscal 2024. Figures as of 17 Nov 2026, 23:23 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
16.5%
Change on fiscal 2024
−5.6 pts
Highest on record
22.1%fiscal 2024
Lowest on record
13.5%fiscal 2023
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Genmab return on equity (ROE), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 22.1% in fiscal 2024 and the lowest 13.5% in fiscal 2023. The fiscal 2025 figure is higher than in 33% of the 3 earlier fiscal years on record, whose median is 20.0%.

History · 4 fiscal years

Return on equity by fiscal year

Genmab return on equity (ROE), year by year

Genmab (GMAB) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202516.5% 5.6 pts down
202422.1% 8.6 pts up
202313.5% 6.5 pts down
202220.0%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Genmab and comparable companies
CompanyReturn on equityFiscal year
Mettler-Toledo International MTD3519.1%2022
Centene CNC-33.4%2025
Genmab GMAB16.5%2025
Illumina ILMN31.2%2025
ResMed RMD23.1%2026
Zoetis ZTS80.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on GMAB

Genmab, figure by figure

Genmab (GMAB) overview: price, valuation and scorecardAll health care companies by market value

Genmab return on equity (ROE): questions and answers

What is Genmab's return on equity?

Genmab (GMAB) earned a return on equity of 16.5% in fiscal 2025 (the year ended December 31, 2025). That is 5.6 percentage points lower than the 22.1% of fiscal 2024.

Is Genmab's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 33% of the 3 earlier fiscal years on record, whose median is 20.0%.

What are the highest and lowest return on equity figures on record for Genmab?

Across the 4 fiscal years on record (2022–2025), the highest was 22.1% in fiscal 2024 and the lowest 13.5% in fiscal 2023.

How is Genmab's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Genmab (GMAB) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/GMAB/roe

Underlying data: Yahoo Finance.